FindTrial
Sign In

Clinical effect of bronchial arterial infusion chemotherapy on epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer

Clinical effect of bronchial arterial infusion chemotherapy on epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011362
Enrollment
Unknown
Registered
2017-05-11
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Interventions

experimental group:bronchial arterial infusion chemotherapy
control group :EGFR-TKIs maintenance therapy

Sponsors

Changxing County Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with stage IV NSCLC were confirmed by histopathology or cytology; 2. Aged=20 years; 3. According to the RECIST evaluation criteria, at least one measurable lesion can be evaluated; 4. ECOGPS score 0 to 1; 5. Hematology and biochemistry examination evaluation organ function is normal.

Exclusion criteria

Exclusion criteria: 1. Use of other chemotherapy, TKI regimen or radiation therapy after TKI disease progression; 2. Patients who had been treated with bronchial arterial infusion; 3. Uncontrolled and symptomatic brain metastases; 4. PS score > 1 or other reasons can not resistant to treatment.

Design outcomes

Primary

MeasureTime frame
Chest computed tomography;—

Countries

China

Contacts

Public ContactBingchen Wu

Changxing County Hospital of Chinese Medicine

wubingchen163@163.com+86 15167238316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026